Friday, 12 June 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 12 June 2026
News

Pharma faces record revenue hit

 Posted 12 June 2026 PM

Analysts are now branding the loss of exclusivity for this long-time blockbuster one of the biggest patent cliff falls in pharma history and our readers were keen to know more, making this our top story this week.

BMS's star performer Eliquis is expected to see sales plummet by an eye-watering 98.6 per cent by 2031, with GlobalData analysts describing it as a near-total revenue wipeout for one of pharma's most dominant brands. More details in: Mega drug faces revenue 'wipeout' 

To see the whole article, please login

Popular

Pharma drops $39M on meetings
Is this pharma's toughest job?
On a roll: Arrotex signs new deal
PBS drug bows out after 35 years
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (22)

Access & Reimbursement (1)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (4)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home